Advancement of the Dragon Heart 7-Series for Pediatric Patients With Heart Failure

Giselle C Matlis1, Thomas C Palazzolo1, Jonathan E M Lawley2,3

  • 1BioCirc Research Laboratory, School of Biomedical Engineering, Science, and Health Systems, Drexel University, Philadelphia, Pennsylvania, USA.

Artificial Organs
|January 11, 2025
PubMed

Insights

Developing the Dragon Heart (DH) pediatric total artificial heart (TAH) shows promise. Computational modeling and prototype testing confirm its centrifugal pump meets pressure-flow requirements for pediatric use.

Area of Science:

  • Biomedical Engineering
  • Cardiovascular Devices
  • Pediatric Cardiology

Background:

  • Pediatric blood pumps lag behind adult devices, creating a critical clinical need.
  • A novel hybrid total artificial heart (TAH), the Dragon Heart (DH), is under development.
  • The DH integrates axial and centrifugal pumps in a compact, magnetically levitated design.

Purpose of the Study:

  • To computationally model and experimentally validate the centrifugal pump component of the pediatric TAH (Dragon Heart).
  • To assess the DH centrifugal pump's ability to meet pediatric pressure and flow requirements.
  • To identify areas for design improvement, specifically regarding fluid stress and hemolytic potential.

Main Methods:

  • Computational modeling was used to iteratively refine the DH centrifugal pump design.
  • Key performance metrics including pressure generation and fluid forces were estimated.
  • A prototype centrifugal pump was manufactured and tested using a blood analog in a hydraulic flow loop.

Main Results:

  • The DH centrifugal pump design achieved target pressures of 60-140 mmHg at flow rates of 1-5 L/min.
  • Experimental data showed strong agreement (<10% deviation) with computational pressure rise predictions.
  • Elevated fluid stress levels were observed in the outflow region, with residence times under 600 ms.

Conclusions:

  • The compact, next-generation Dragon Heart centrifugal pump design meets essential pressure-capacity requirements for pediatric TAH applications.
  • Further development is necessary to mitigate hemolytic potential.
  • Integration of magnetic suspension for full rotor levitation is a key next step.
Abstract

Related Concept Videos

Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
515
Heart Failure Drugs: &#946;-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
314
Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.5K
Development of the Heart01:27

Development of the Heart

The development of the human heart, a crucial organ, commences from the mesoderm on the 18th or 19th day after fertilization. This process initiates in the cardiogenic area, a group of mesodermal cells at the embryo's head end, which evolves into elongated strands known as cardiogenic cords. These cords undergo a transformation to form hollow-centered endocardial tubes.
As the embryo undergoes lateral folding, these paired tubes approach each other, merging into a single primitive heart...
861
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
338
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
381